Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-26-033429
Filing Date
2026-05-11
Accepted
2026-05-11 16:03:45
Documents
63
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q bcax-20260331.htm   iXBRL 10-Q 1727155
2 EX-31.1 exhibit311q1-26.htm EX-31.1 10473
3 EX-31.2 exhibit312q1-26.htm EX-31.2 10399
4 EX-32.1 exhibit321q1-26.htm EX-32.1 7600
10 bcax-20260331_g1.jpg GRAPHIC 810093
  Complete submission text file 0001628280-26-033429.txt   8254371

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20260331.xsd EX-101.SCH 35433
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcax-20260331_cal.xml EX-101.CAL 49499
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcax-20260331_def.xml EX-101.DEF 207389
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20260331_lab.xml EX-101.LAB 511987
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20260331_pre.xml EX-101.PRE 355958
67 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20260331_htm.xml XML 642707
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42271 | Film No.: 26963064
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)